What is the French Biotech Tour?

The FRENCH BIOTECH TOURS aim to provide industry professionals with essential contacts and strategic partnership opportunities in a specific therapeutic field. Former participants include large pharmaceutical laboratories (Abbott, Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Novartis, Sanofi Pasteur, Sanofi, Merck, Pfizer, etc.), 120 American biotech companies and 50 French companies.

The upcoming  FRENCH BIOTECH TOUR 2012 will focus on IMMUNOLOGY, INFLAMMATION and NEUROLOGY. It will stop by SAN FRANCISCO on October, 16th and SAN DIEGO on October, 18th. These partnering events are FREE OF CHARGE for US-BASED COMPANIES and includes:

• Pre-arranged, one-on-one business meetings (20 to 30 minutes each)
• Presentations from cutting-edge companies in their field
• Networking opportunities

For additional information, please consult the provisional PROGRAM.

Please visit our TESTIMONIALS page to know what previous attendees are saying about the French Biotech Tour.

1 - REGISTER NOW! Registration is free of charge for US-based companies and filling up fast! Be sure to reserve your spot and take advantage of these opportunities to meet new partners. Just complete your company profile form and state your objectives for new partnerships. Don't forget to let us know which event you want to attend (San Diego or San Francisco) by choosing US-SAN Francisco or US-San Diego in the "category" tab. 

2 - REQUEST MEETINGS WITH CUTTING-EDGE COMPANIES: Find companies that you are interested in working with and let us know that you want to meet them! Deadline to request meetings: October 5th, 2012.

3 - SUBMIT YOUR PRESENTATION REQUEST: Want to gain more exposure by presenting your company at the FRENCH BIOTECH TOUR 2012? Let us know by checking the box when you register. Deadline to submit PowerPoint slides: October 10th , 2012.

The FRENCH BIOTECH TOUR is only open to organizations involved in drug discovery/development  and diagnostics (CRO/CMO included) in the fields of Immunology, Inflammation and Neurology. Service providers and consultancy firms will be considered on a case by case basis. Please CONTACT US for more information.

Yves GERMANI:  - +1

Clémence D'ASCANIO:  - +1

 Charles-Henry DION:  - +1